Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06140472
Other study ID # D19-P019
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date December 11, 2019
Est. completion date June 30, 2024

Study information

Verified date November 2023
Source Centre Hospitalier St Anne
Contact Julie Dupouy, Nurse
Phone 01.45.65.80.64
Email j.dupouy@ghu-paris.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study is to evaluate the effectiveness of the addition of nursing follow-up and the PHOENIX application, a personalized and self-adaptive Smartphone application, on the management of craving in patients with addictive disorders followed on an outpatient basis.


Description:

Addictive disorders are a public health priority. The management of addictive disorders aims to reduce addictive behaviour or abstinence, implying that the patient can overcome the urge to engage in this behaviour, a symptom called craving. Craving, as a major motivational substrate for addictive behaviour, is a preferred therapeutic target for the management of addictive disorders. However, to date, there are no fully effective drugs or psychological interventions. Smartphone applications seem to have an interest in this context, with many advantages: accessibility, anonymity, ease of access and low cost. Sainte Anne's Hospital Moreau de Tour facility (Paris, France) was one of the pioneering centres in the management of addictive disorders. The nursing team has developed expertise in this field. Patients report difficulties to nurses about managing their craving on their own, and ask for more frequent interviews or even daily support. During practice analysis meetings, caregivers sought innovative solutions to optimize this care. Our team has designed the PHOENIX application, which allows us to support patients in real time who wish to reduce or stop their addictive behaviours. Used between two consultations, it targets craving, without being specific to a product or addictive behaviour. When the patient has a craving, PHOENIX identifies the situation and proposes the most appropriate strategy to avoid using. Strategies are personalized and self-adaptive. The application allows caregivers to monitor patients' progress and progress. Hypothesis of this study: The PHOENIX application used as a complement to nursing care will allow a better management of craving and a decrease in relapses compared to usual care (usual care: multidisciplinary care including nursing care).


Recruitment information / eligibility

Status Recruiting
Enrollment 160
Est. completion date June 30, 2024
Est. primary completion date December 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Being 18 and 65 years old, any sex - Speak and read French - Have a Smartphone (Android operating system or IOS) - Present an evaluated addictive disorder in a structured clinical interview (MINI, adapted to the criteria of DSM-5: substance use disorder according to DSM-5 and bulimia nervosa; National Opinion DSM Screen (NODS), adapted to the criteria of DSM-5: pathological gambling; NODS, adapted to the diagnostic criteria proposed by Carnes: sexual addiction ; MINI) - Be followed on an outpatient basis - Prior informed written consent of the patient or his or her legal representative - Benefit from a French social protection system Exclusion Criteria: - Have a current untreated and/or unstabilized psychiatric disorder (assessed by MINI) - Have a severe cognitive impairment assessed during the clinical interview, which does not allow you to focus your attention or use the working memory required by the application. - Pregnant or breastfeeding women - Participant in another clinical trial

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Phoenix
Specific individualized nurse follow-up using the PHOENIX application.
Journal de bord
Regular nursing follow-up, with the use of an electronic journal.

Locations

Country Name City State
France Hospices Civiles de Lyon Lyon
France CHU de Nantes Nantes

Sponsors (2)

Lead Sponsor Collaborator
Centre Hospitalier St Anne Direction Générale de l'Offre de Soins

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary median craving intensity at 6 months Measurement of craving intensity with an analog visual scale (AVS) between 0 (no craving) and 10 (maximum imaginable craving), informed during craving episodes by the patient via the PHOENIX application or the electronic journal. Over the last 30 days before the visit at 6 months 6 months visit
Secondary Number of cravings The cravings will be informed by the patient during craving episodes via the PHOENIX application or the electronic journal 0,3,6 and 12 months visit
Secondary Daily frequency of cravings The cravings will be informed by the patient during craving episodes via the PHOENIX application or the electronic journal 0,3,6 and 12 months
Secondary Median of the intensity of the cravings Measurement of craving intensity with an analog visual scale (AVS) between 0 (no craving) and 10 (maximum imaginable craving), informed during craving episodes by the patient via the PHOENIX application or the electronic journal. Over the last 15 days before the visit at 0, 3 and 12 months 0, 3, and 12 months visit
Secondary Number of addictive behavioural episodes Addictive behaviors will be informed via the phoenix application or the electronic journal 0,3,6 and 12 months
Secondary Frequency of addictive behavioural episodes Addictive behaviors will be informed via the phoenix application or the electronic journal 0,3,6 and 12 months
Secondary Type of addictive behavioural episodes Addictive behaviors will be informed via the phoenix application or the electronic journal 0,3,6 and 12 months visit
Secondary Severity of addictive disorder: addictive substance disorder or pathological gambling Severity of the disorder assessed by the number of diagnostic criteria for addictive substance disorder or pathological gambling on the Diagnostic and Statistical Manuel of mental disorders (DSM-5). 0,3,6 and 12 months
Secondary Severity of addictive disorder: Yale Food Addiction Scale (YFAS) food addiction score for bulimia nervosa Severity of the food addiction for bulimia nervosa is assessed by the Yale Food Addiction Scale (YFAS).
The YFAS assesses addiction-like eating of palatable foods based on the 11 diagnostic criteria for substance use disorder in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). No Food Addiction = 0-1 symptoms/score; Mild Food Addiction = 2 or 3 symptom/score; Moderate Food Addiction = 4 or 5 symptom/score; Severe Food Addiction = 6 or higher symptom/score
0 and 12 months visit
Secondary Severity of addictive disorder: sexual addiction (Carnes criteria) Severity of the disorder assessed by the number of positive responses in the Carnes criteria. Carnes criteria consists of 25 yes/no questions. If the answer is "yes" to 13 or more questions, the patient can be diagnosed as a sex addict (range: 0-25). 0,3,6 and 12 months visit
Secondary Impulsivity (UPPS scale) Impulsivity is assessed using the UPPS scale (Urgency, Premeditation (lack of), Perseverance (lack of), Sensation seeking. The UPPS impulsivity scale is a 45-item self-questionnaire that measures impulsivity by exploring: urgency (12 items: range 12-48), lack of forethought (11 items; range:11-44), lack of perseverance (10 items; range:10-40) and sensation seeking (12 items; range:12-48). For each subdimension, a high score indicates a high level of impulsivity. 0,3,6 and 12 months
Secondary Number of strategies to deal with craving according to the type of addictive behaviour The strategies will be provided through the application or the electronic journal 0,3,6 and 12 months
Secondary Multidimensional evaluation of coping (Brief Cope scale by Muller and Spitz) The multidimensional evaluation of coping is carried out using the Brief Coping Orientation to Problems Experienced (Brief COPE) ,28-item self-questionnaire. The Brief COPE contains 28 statements and 14 scales, each consisting of 2 statements. It is a self-administered questionnaire. It is available in 2 formats: 1) dispositional, which is designed to assess how people habitually respond to stressful situations, and 2) situational, which is designed to assess how people responded to a specific event or context that has recently become a source of stress. Only the verb tense varies between statements in the two formats.
The respondent uses a 4-point scale to give his/her answer to each statement: 1 - not at all; 2 - a little; 3 - a lot; 4 - completely.
The answers obtained are added together for each scale. Higher scores on a scale indicate greater use of this coping mechanism.
0,3,6 and 12 months
Secondary Anxiety: Beck's inventory for anxiety (BAI) The anxiety assessment is carried out using Beck's inventory for anxiety (BAI). The Beck Anxiety Inventory (BAI) is a 21-question multiple-choice self-report inventory used to measure the severity of anxiety. The questions used in this measure ask to describe common symptoms of anxiety that the subject has experienced in the last week (including the day on which the measure is taken).
The BAI contains 21 questions, each answer being scored on a scale value of 0 (not at all) to 3 (severely). Higher total scores indicate more severe anxiety symptoms.
The standardized cutoffs are:
0-7: Minimal 8-15: Mild 16-25: Moderate 26-63: Severe
0,3,6 and 12 months
Secondary Depression: Beck's depression inventory The Beck Depression Inventory (BDI), is a multiple-choice self-report inventory for measuring the severity of depression.
The BDI, consisted of twenty-one questions about how the subject has been feeling in the last week. Each question had a set of at least four possible responses, ranging in intensity:
(0) I do not feel sad
I feel sad.
I am sad all the time, and I cannot snap out of it.
I am so sad or unhappy that I cannot stand it.
When the test is scored, a value of 0 to 3 is assigned for each answer, and then the total score determines the depression's severity. The standard cut-off scores were as follows:
0-9: indicates minimal depression 10-18: indicates mild depression 19-29: indicates moderate depression 30-63: indicates severe depression. Higher total scores indicate more severe depressive symptoms.
0,3,6 and 12 months
Secondary Quality of life: World Health Organization Quality of Life (WHOQOL 26 scale) The World Health Organization Quality of Life (WHOQOL26) assesses subjective health-related quality of life in a 26-item self-administered questionnaire.
The WHOQOL26 scale investigates the quality of life in four domains: physical health (7 items), psychological health (6 items), social relationships (3 items) and environmental health (8 items); it also contains QOL and general health items. Each item of the WHOQOL26 is scored on a five-point ordinal scale. The scores are then linearly transformed into a 0-100 scale.
0,3,6 and 12 months
Secondary Self-esteem (Coopersmith inventory) The Coopersmith's Self-Esteem Inventory assesses general, professional, social and family self-esteem; the total is the sum of these four components. The test comprises 58 items; the responses are "looks like me" or "doesn't look like me." The score is composed of several subscales: General (26 items), Social (8 items), Professional (8 items), Family (8 items) and Lie (8 items). The total score (50 items) is obtained by summing the General, Social, Professional and Family subscales. The Lying scale is more of a social desirability scale used to assess patient authenticity in general assessment. 0,3,6 and 12 months
Secondary Use of healthcare related to addictive disorder: Hospitalisation Number of hospitalization days related to addiction 0,3,6 and 12 months
Secondary Use of healthcare related to addictive disorder: emergency department accesses Number of emergency department accesses related to addiction 0,3,6 and 12 months
See also
  Status Clinical Trial Phase
Terminated NCT03576768 - QuitFast: Evaluating Transcranial Magnetic Stimulation as a Tool to Reduce Smoking Directly Following a Quit Attempt N/A
Not yet recruiting NCT06026982 - Gut Health and the Effect on Substance and Alcohol Cravings Early Phase 1
Not yet recruiting NCT05535101 - Non-invasive Brain Stimulation in Patients With Methamphetamine Use Disorder N/A
Completed NCT05074524 - Repetitive Transcranial Magnetic Stimulation to Reduce Heroin Cravings N/A
Completed NCT03112824 - Functional Assessment of Ashwagandaha Root Extract During Weight Loss N/A
Completed NCT03758027 - CARESS: An Investigation of Effects of CARESS N/A
Not yet recruiting NCT03217929 - Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) for Food Craving in Obese Individuals. N/A
Completed NCT01030289 - The Effectiveness of Transcranial Direct Current Stimulation (tDCS) in Decreasing Food Cravings N/A
Withdrawn NCT04077385 - Memory-Updating Technique to Reduce Food Craving and High Calorie Food Intake Among Individuals With Overweight/Obesity N/A
Completed NCT04310423 - An Inflammatory Challenge Using Endotoxin Phase 2
Recruiting NCT05076201 - Process of Regulation in Addictions: Vulnerability Emotional Factors to Craving N/A
Not yet recruiting NCT06129461 - A Single Session Self-guided Acceptance-based Digital Intervention Targeting Food Cravings in Pregnancy N/A
Recruiting NCT04338178 - Efficacy of a Cognitive - Affective - Addictive Based Intervention to Decrease Food Craving in Obese Patients. N/A
Terminated NCT04162145 - BRIDGE Device for Treatment of Opioid Withdrawal N/A
Completed NCT05430685 - The Impact of Ashwagandha on Perceived Stress, Sleep and Food Cravings in College Students Phase 2
Recruiting NCT04154111 - Theta Burst Stimulation as a Tool to Decrease Drinking in Treatment-seeking Alcohol Users N/A
Recruiting NCT05277714 - Neurofeedback Based on Near-infrared Spectroscopy as a Therapy for Food Addiction in Obese Subjects. N/A
Completed NCT04936594 - TMS for Smoking Cessation in PLWHA Cessation in People Living With HIV/AIDS (PLWHA) N/A
Enrolling by invitation NCT05336188 - Neurocognitive Mechanisms Underlying Smartphone-Assisted Prevention of Relapse in Opioid Use Disorder Phase 2
Recruiting NCT04850664 - Computerized Chemosensory-Based Orbitofrontal Cortex (CBOT) for Opioid Use Disorder Phase 2